肝细胞癌放疗现状与进展

doi:10.3760/cma.j.issn.1673-422X.2014.04.018

摘要/Abstract

摘要： 放疗是无手术指征肝细胞肝癌（HCC）患者的主要治疗方法，包括内放疗、三维适形放疗、三维调强放疗(IMRT)、立体定向放疗及放疗联合肝动脉化疗栓塞（TACE）等。对于微小病灶、外照射后残存或复发的病灶，内放疗可有目的性地放置放射性核素以提高靶器官辐射量，减少正常组织的辐射量。对于肿瘤边界不清，有癌栓、淋巴结转移或局部复发的患者，三维适形放疗、IMRT及放疗联合TACE则可以更好地使高剂量分布形状与靶区形状在三维空间上一致，提高局部控制率。

关键词: 癌, 肝细胞, 治疗, 放射疗法

Abstract: Radiation therapy is a primary treatment for the unresectable hepatocellular carcinoma (HCC), including internal radiotherapy, threedimensional conformal radiotherapy, threedimensional intensity modulated radiotherapy (IMRT), stereotactic radiotherapy and radiotherapy combined with transcatheter arterial chemoembolization (TACE). For small lesions, residual or recurrent lesions after external irradiation, the internal radiotherapy can purposefully place radionuclides to increase the amount of radiation in target organs and reduce the amount of radiation in normal tissue. For the patients with unclear tumor boundary, thrombosis, lymph node metastasis or local recurrence, threedimensional conformal radiotherapy, IMRT and radiotherapy combined with TACE can better make the target highdose distribution shape fit with threedimensional space accurately, and improve the local control rate.

Key words: Carcinoma, hepatocellular, Therapy, Radiotherapy

梁宁, 孙丰凯, 张建东. 肝细胞癌放疗现状与进展[J]. 国际肿瘤学杂志, 2014, 41(3): 216-220.

LIANG Ning, SUN Feng-Kai, ZHANG Jian-Dong. Current situation and progress of hepatocellular carcinoma radiotherapy[J]. Journal of International Oncology, 2014, 41(3): 216-220.

参考文献

［1］ HernandezGea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma［J］. Gastroenterology, 2013, 144(3): 512527. ［2］ Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors［J］. Eur Rev Med Pharmacol Sci, 2010, 14(4): 249258. ［3］ Qian J, Luo Y, Gu X, et al. Inhibition of SENP6induced radiosensitization of human hepatocellular carcinoma cells by blocking radiationinduced NFκB activation［J］. Cancer Biother Radiopharm, 2013, 28(3): 196200. ［4］ Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium90 radioembolization for intermediateadvanced hepatocellular carcinoma: a phase 2 study［J］. Hepatology, 2013, 57(5): 18261837. ［5］ Kumar A, Srivastava DN, Chau TT, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDDlabeled iodized oil for treatmentprospective multicenter clinical trial［J］. Radiology, 2007, 243(2): 509519. ［6］ Liu MT, Li SH, Chu TC, et al. Threedimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization［J］. Jpn J Clin Oncol, 2004, 34(9): 532539. ［7］ Kim DY, Park W, Lim DH, et al. Threedimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma［J］. Cancer, 2005, 103(11): 24192426. ［8］ Kim TH, Kim DY, Park JW, et al. Threedimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable［J］. Am J Clin Oncol, 2006, 29(6): 568575. ［9］ Wang W, Feng X, Zhang T, et al. Prospective evaluation of microscopic extension using wholemount preparation in patients with hepatocellular carcinoma: definition of clinical target volume for radiotherapy［J］. Radiat Oncol, 2010, 5: 73. ［10］ Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume［J］. Int J Radiat Oncol Biol Phys, 2010, 76(2): 467476. ［11］ Hallman JL, Mori S, Sharp GC, et al. A fourdimensional computed tomography analysis of multiorgan abdominal motion［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): 435441. ［12］ Dawson LA, Brock KK, Kazanjian S, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2001, 51(5): 14101421. ［13］ Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirusp53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma［J］. J Cancer Res Clin Oncol, 2010, 136(4): 625630. ［14］ Tse RV, Hawkins M, Lockwood G, et al. Phase Ⅰ study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma［J］. J Clin Oncol, 2008, 26(4): 657664. ［15］ Kwon JH, Bae SH, Kim JY, et al. Longterm effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer［J］. BMC Cancer, 2010, 10: 475. ［16］ Higuchi T, Kikuchi M, Okazaki M, et al. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases［J］. Cancer, 1994, 73(9): 22592267. ［17］ Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and metaanalysis［J］. Radiother Oncol, 2009, 92(2): 184194. ［18］ Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma［J］. Liver Int, 2005, 25(6): 11891196. ［19］ Zhou ZH, Liu LM, Chen WW, et al. Combined therapy of transcatheter arterial chemoembolisation and threedimensional conformal radiotherapy for hepatocellular carcinoma［J］. Br J Radiol, 2007, 80(951): 194201. ［20］ Ni S, Liu L, Shu Y. Sequential transcatheter arterial chemoembolization, threedimensional conformal radiotherapy, and highintensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients［J］. J Biomed Res, 2012, 26(4): 260267. ［21］ Tournoux C, Paoletti X, Barbare JC, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies［J］. Cancer Treat Rev, 2007, 33(8): 762763. ［22］ Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and threedimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus［J］. Int J Radiat Oncol Biol Phys, 2010, 78(1): 180187.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[7]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[10]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[11]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[15]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.